Scilit logo
  • Rankings
  • Search Publications
    Cited-by Search
  • Sources
  • Publishers
  • Scholars
    Top Cited Scholars
  • Organizations
  • Scilit
    About Us
    Advisory Board
    Data Sources
    Career
    Support / Contact
    User Guide
    Publisher User
    Search Function
    Rankings Function
    API Resource
    Scilit Knowledge
    Metrics
    Scilit Recognitions
    Publications Classification
    Media
    News
    Blog
Register
  1. Home
  2. Publications
  3. Supplementary Figure 10 from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study
  1. Home
  2. Publications
  3. Supplementary Figure 10 from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study

Supplementary Figure 10 from Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy bb21217 for Relapsed and Refractory Multiple Myeloma: Results from the Phase I CRB-402 Study

Authors:
  • MAMelissa Alsina
    Melissa Alsina
  • NSNina Shah
    Nina Shah
  • SJSundar Jagannath
    Sundar Jagannath
  • JKJonathan L. Kaufman
    Jonathan L. Kaufman
  • DSDavid Siegel
    David Siegel
  • NMNikhil C. Munshi
    Nikhil C. Munshi
  • JRJacalyn Rosenblatt
    Jacalyn Rosenblatt
  • YLYi Lin
    Yi Lin
  • AJAndrzej J. Jakubowiak
    Andrzej J. Jakubowiak
  • BDBenjamin A. Derman
    Benjamin A. Derman
  • ALAojun Li
    Aojun Li
  • PMPingping Mao
    Pingping Mao

Open Access
Publisher website
Google Scholar
  • 2 April 2026
    • other
    • Published by American Association for Cancer Research (AACR)
    • DOI:10.1158/2326-6066.31923868
Abstract
Functional persistence of CAR T cells may not be sufficient for durable response, as determined by VCN persistence and sBCMA levels
Keywords
  • CLINICAL TRIAL RESULTS
  • PHASE I CLINICAL TRIALS
  • HEMATOLOGICAL CANCERS
  • MYELOMAS
  • IMMUNOTHERAPY
Scilit logo

Have questions? Email us at support@scilit.com

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.

MDPI initiatives

  • MDPI Journals
  • MDPI Books
  • Sciforum
  • Proceedings Series
  • Preprints.org
  • SciProfiles
  • Encyclopedia
  • JAMS

Legal

  • Privacy
  • Terms
  • About
  • Contact
  • Disclaimer

Follow us

  • facebook icon
  • x icon
  • linkedin icon

Join us

  • Career

© 2026 MDPI (Basel, Switzerland) unless otherwise stated.